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ABSTRACT
Skin and soft tissue infections are the most
common presentations of invasive Streptococcus
agalactiae infections. This study reviewed 71
patients in a medical centre in southern Taiwan
with S. agalactiae soft tissue infections. The
mortality rate was 7%, and 11% of patients lost
their extremities following extensive tissue nec-
rosis. Critical illness and the presence of cuta-
neous ulceration heralded a fatal prognosis.
Risk-factors for amputation of limbs included
advanced age, cutaneous ulceration and poly-
microbial infection. It was concluded that inva-
sive S. agalactiae soft tissue infections, as with
infections caused by Streptococcus pyogenes, can
also lead to substantial morbidity and mortality
in non-pregnant adults.
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Since the 1970s, group B Streptococcus (GBS;
Streptococcus agalactiae) has been recognised as a
pathogen, mainly in neonates and peripartum
women. Despite sporadic reports of GBS infec-
tions in non-pregnant adults, this organism was
only recognised as an important pathogen in
non-pregnant adults following intensive popula-
tion-based surveillance in the 1980s and 1990s
[1,2]. Skin and soft tissue infections are the most
common presentations of invasive GBS infections,
accounting for the infectious foci of 15–40% of
bacteraemic episodes [1,2]. The present study
reviewed the medical records of all isolates
identified as S. agalactiae from blood or other
sterile body sites that were associated with a
diagnosis of soft tissue infection between June
1991 and June 1999; patients aged < 18 years and
females who were pregnant or in the peripartum
period were excluded.
Soft tissue infections were classified into two
types according to the spread of infection at the
anatomical level and whether the presence of
necrosis indicated surgery [3]. Critical illness
was assessed at the time of the development of
disease using the Pittsburgh bacteraemia score
[4] and the Simplified Acute Physiology Score
(SAPS) II [5].
b-Haemolytic streptococci with a positive test
result for CAMP factor were also tested for
Lancefield group B cell wall antigen with group-
specific antiserum (Streptex; Murex Biotech, Dart-
ford, UK). Antimicrobial susceptibilities were
determined by the NCCLS agar dilution method
[6]. Serotypes were determined by agglutination
with six type-specific agglutinins against GBS
serotypes Ia, Ib, II, III, IV and V (Denka Seiken,
Tokyo, Japan) as described previously [7]. The
chi-square test or two-tailed Fisher’s exact test
was employed for categorical variables, and the
Mann–Whitney U-test was used for continuous
variables. Multivariate analysis was done by
stepwise logistic regression if there was signifi-
cant association in the univariate analysis.
Seventy-one patients with soft tissue infections
were identified during the study period. Table 1
shows their demographic information and under-
lying conditions. The average annual incidence
was 4.7 cases ⁄ 10 000 admissions. The age of the
patients ranged from 18 to 85 years; two (2.8%)
patients were aged < 20 years, 34 (47.9%) were
aged 20–59 years, and 35 (49.3%) were aged
> 60 years. The clinical diagnoses of GBS soft
tissue infections included cellulitis, diabetic foot
infections, subcutaneous abscess, infected wound,
pyomyositis and necrotising fasciitis (Table 2).
Twenty-five (35.2%) patients had polymicrobial
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infections, with the most common accompanying
organisms being Gram-positive cocci such as
Staphylococcus aureus or coagulase-negative sta-
phylococci. Of the 71 cases, 11 (15.5%) involved
more than one chronic underlying illness. Seven-
teen (23.9%) patients did not have any obvious
underlying disease (Table 1), and these patients
were younger than those with an underlying
disease (p < 0.0001).
All isolates were susceptible to penicillin, cefo-
taxime, ofloxacin and vancomycin. Susceptibility
to clindamycin, azithromycin, erythromycin and
chloramphenicol varied, ranging from 53.5% to
71.4%. Most (95%) isolates were resistant to
tetracycline. Capsular serotyping was performed
for 40 isolates. Type V was the most frequent
serotype (32.5%), followed by types III (20%), Ia
(15%), Ib (7.5%) and IV (2.5%). The mean
duration of parenteral and oral antimicrobial
therapy was 10.8 days for type I and 22.4 days
for type II soft tissue infections, respectively
(p 0.008) (Table 2). The overall mortality rate
was 7%.
Multivariate analysis showed that critical ill-
ness at admission (p < 0.001), the presence of
cutaneous ulceration (including a decubitus ulcer
or an infected ulcer on a diabetic foot) (p 0.014)
heralded a poor prognosis. There were 31 cases
requiring surgical intervention. Eight cases
evolved into limb-threatening infections with
eventual amputation. The significant risk-factors
for amputation were advanced age (p 0.018), the
presence of cutaneous ulceration (p 0.002) and
polymicrobial infection (p 0.0015).
The annual incidence of GBS soft tissue infec-
tions in non-pregnant adults rose from 0.86
cases ⁄ 100 000 population in 1982, to 1.54 in
1990, to 1.71 in 1996 [1,2,8], which is similar to
the incidence (1.5 cases ⁄ 100 000 population) of
soft tissue infections caused by Streptococcus
pyogenes [9], which has been regarded as the
most common cause of streptococcal skin and
soft tissue infection [10,11]. A report of b-hae-
molytic streptococcal soft tissue infections in
India found that GBS was the second most
common isolate (11%) after S. pyogenes (75%)
[10,12]. Based on the overall trend and clinical
observations, GBS should be recognised as a
significant cause of soft tissue infections among
non-pregnant adults.
Serotypes Ia, Ib, II, III and, most recently, V
have been associated with severe invasive disease
[8]. In the present study, the most common GBS
serotype causing soft tissue infections was type V,
followed by types III and Ia. These three serotypes
account for 67% of the circulating serotypes that
cause invasive soft tissue infections. The antimi-
crobial susceptibility data support the use of
penicillin G, ampicillin and other semi-synthetic
penicillins as the drugs of choice for the treatment
of GBS infections [7,8,13,14]. Macrolides, which
were the options recommended previously for
patients with penicillin allergy, appear to be
losing their activity against GBS in Taiwan [15].
Amputation of limbs was occasionally una-
voidable in cases of serious soft tissue or muscu-
loskeletal infections in diabetic patients, and was
required in the present study for eight (34.8%) of
the 23 diabetic patients with GBS infections in
their extremities. Additionally, polymicrobial
infections were found to greatly threaten the
viability of an infected extremity, which might be
Table 1. Demographic data and underlying conditions of
71 patients with soft tissue infections caused by Strepto-
coccus agalactiae
Characteristic No. (%)
Age (years)
Mean ± SD 55.5 ± 15.9
Range 18–85
Sex
Male 40 (56.3)
Female 31 (43.7)
Place of acquisition
Hospital 7 (9.9)
Community 64 (90.1)
Underlying conditiona
Diabetes mellitus 39 (54.9)
Malignant neoplasms 11 (15.5)
Use of glucocorticoids 4 (5.6)
Heart failure 3 (4.2)
Liver cirrhosis 2 (2.8)
Neurological disease 2 (2.8)
Systemic lupus erythematosus 2 (2.8)
Burn injury 1 (1.4)
Chronic obstructive pulmonary disease 1 (1.4)
No underlying disease 17 (23.9)
aPatients may have more than one underlying condition or diagnosis.
Table 2. Infectious diagnosis and treatment course for 71
patients with soft tissue infections caused by Streptococcus
agalactiae
Diagnosis No. (%)
Treatment course,
days (mean ± SD)
Type I 19 (26.8) 10.8 ± 5.2
Cellulitis 17 (23.9) 10.5 ± 5.0
Non-limb-threatening diabetic foot infection 2 (2.8) 13.5 ± 7.8
Type II 52 (73.2) 22.4 ± 16.1
Limb-threatening diabetic foot infection 15 (21.1) 29.3 ± 13.7
Subcutaneous abscess 12 (16.9) 13.5 ± 9.7
Infected wound 11 (15.5) 22.6 ± 19.0
Pyomyositis 10 (14.1) 31.2 ± 19.6
Necrotising fasciitis 4 (5.6) 21.3 ± 20.1
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related to the additive or synergic virulence of a
mixed flora.
The mortality rate of invasive GBS infections in
non-pregnant adults varies greatly, ranging from
8% [16] to 32% [2]. Factors associated with a poor
outcome among patients with invasive GBS infec-
tions have been described previously [14,17].
However, such information is scant with respect
to GBS soft tissue infections. The present study
found that critical illness at admission and cuta-
neous ulceration were indicative of a poor clinical
outcome in GBS soft tissue infections, with a
fatality rate of 7%.
In conclusion, invasive soft tissue infections
caused by GBS are not uncommon in non-preg-
nant adults, especially the elderly and patients
with diabetes mellitus, and can result in substan-
tial morbidity and mortality. Prolonged duration
of antimicrobial therapy and early surgical inter-
ventions are indicated for life-threatening infec-
tions.
REFERENCES
1. Farley MM, Harvey RC, Stull T et al. A population-based
assessment of invasive disease due to group B strepto-
coccus in non-pregnant adults. N Engl J Med 1993; 328:
1807–1811.
2. Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower
A, Broome CV. Invasive group B streptococcal disease in
adults: a population-based study in metropolitan Atlanta.
JAMA 1991; 266: 1112–1114.
3. Smith AJ, Daniels T, Bohnen JM. Soft tissue infections and
the diabetic foot. Am J Surg 1996; 6A(suppl): 7–12.
4. Yu VL, Chiou CC, Feldman C et al. An international
prospective study of pneumococcal bacteremia: correla-
tion with in vitro resistance, antibiotics administered, and
clinical outcome. Clin Infect Dis 2003; 37: 230–237.
5. Le Gall JR, Lemeshow S, Saulnier F. A new Simpli-
fied Acute Physiology Score (SAPS II) based on a
European ⁄North American multicenter study. JAMA 1993;
270: 2957–2963.
6. National Committee for Clinical Laboratory Standards.
Performance standards for antimicrobial susceptibility testing,
8th informational supplement. M100-S8. Villanova, PA:
NCCLS, 1998.
7. Ko WC, Lee HC, Wang LR, Lee CT, Liu AJ, Wu JJ. Sero-
typing and antimicrobial susceptibility of group B strep-
tococcus over an eight-year period in southern Taiwan.
Eur J Clin Microbiol Infect Dis 2001; 20: 334–339.
8. Tyrrell GJ, Senzilet LD, Spika JS et al. Invasive disease due
to group B streptococcal infection in adults: results from a
Canadian, population-based, active laboratory surveil-
lance study—1996. Sentinel Health Unit Surveillance Sys-
tem Site Coordinators. J Infect Dis 2000; 182: 168–173.
9. Davies HD, McGeer A, Schwartz B et al. Invasive group A
streptococcal infections in Ontario, Canada. N Engl J Med
1996; 335: 547–554.
10. Mathur P, Kapil A, Das B et al. Invasive beta-haemolytic
streptococcal infections in a tertiary care hospital in nor-
thern India. J Med Microbiol 2002; 51: 791–792.
11. Bisno AL, Stevens DL. Streptococcal infections of skin and
soft tissues. N Engl J Med 1996; 334: 240–245.
12. Mathur P, Kapil A, Das B et al. Spectrum of beta-haemo-
lytic streptococcal soft tissue infections at a tertiary care
hospital of north India. Ind J Med Res 2003; 118: 187–191.
13. Farley MM. Group B streptococcal disease in nonpregnant
adults. Clin Infect Dis 2001; 33: 556–561.
14. Trivalle C, Martin E, Martel P, Jacque B, Menard JF,
Lemeland JF. Group B streptococcal bacteremia in the
elderly. J Med Microbiol 1998; 47: 649–652.
15. Hsueh PR, Teng LJ, Lee LN, Ho SW, Yang PC, Luh KT.
High incidence of erythromycin resistance among clinical
isolates of Streptococcus agalactiae in Taiwan. Antimicrob
Agents Chemother 2001; 45: 3205–3208.
16. Bayer AS, Chow AW, Anthony BF, Guze LB. Serious
infections in adults due to group B streptococci: clinical
and serotypic characterization. Am J Med 1976; 61: 498–503.
17. Jackson LA, Hilsdon R, Farley MM et al. Risk factors for
group B streptococcal disease in adults. Ann Intern Med
1995; 123: 415–420.
RESEARCH NOTE
Prevalence of erythromycin and
clindamycin resistance among Streptococcus
agalactiae isolates in Germany
T. E. Schoening1, J. Wagner2 and M. Arvand3
1Hygiene-Institut, Universita¨t Heidelberg,
Heidelberg, 2Institut fu¨r Infektionsmedizin,
Charite´ Universita¨tsmedizin Berlin, Campus
Benjamin Franklin, Berlin and 3Institut fu¨r
Medizinische Mikrobiologie, Virologie und
Hygiene, Universita¨t Rostock, Rostock, Germany
ABSTRACT
The antimicrobial susceptibilities of 338 clinical
Streptococcus agalactiae isolates from two geo-
graphical regions in Germany were determined
by agar dilution. All isolates were susceptible to
penicillin, cefotaxime and vancomycin. The over-
all frequencies of erythromycin and clindamycin
resistance were 11% and 4.7%, respectively.
Determination of resistance phenotypes among
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